Cerebral Palsy

Categories: Eye diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Cerebral Palsy

MalaCards integrated aliases for Cerebral Palsy:

Name: Cerebral Palsy 12 74 52 53 29 54 6 42 3 15 37 17 71 32
Infantile Cerebral Palsy 12 71
Cerebral Palsy, Mixed 71
Mixed Cerebral Palsy 52
Palsy, Cerebral 39
Palsy Cerebral 74


External Ids:

Disease Ontology 12 DOID:1969
MeSH 43 D002547
NCIt 49 C34460
SNOMED-CT 67 128188000
ICD10 32 G80 G80.9
UMLS 71 C0007789 C0392549 C0751024

Summaries for Cerebral Palsy

NINDS : 53 The term cerebral palsy refers to a group of neurological disorders that appear in infancy or early childhood and permanently affect body movement, muscle coordination, and balance. CP affects the part of the brain that controls muscle movements.  The majority of children with cerebral palsy are born with it, although it may not be detected until months or years later. The early signs of cerebral palsy usually appear before a child reaches 3 years of age. The most common are a lack of muscle coordination when performing voluntary movements (ataxia); stiff or tight muscles and exaggerated reflexes (spasticity); walking with one foot or leg dragging; walking on the toes, a crouched gait, or a “scissored” gait; and muscle tone that is either too stiff or too floppy. Other neurological symptoms that commonly occur in individuals with CP include seizures, hearing loss and impaired vision, bladder and bowel control issues, and pain and abnormal sensations. A small number of children have CP as the result of brain damage in the first few months or years of life, brain infections such as bacterial meningitis or viral encephalitis, or head injury from a motor vehicle accident, a fall, or child abuse. The disorder isn't progressive, meaning that the brain damage typically doesn't get worse over time. Risk factors associated with CP do not cause the disorder but can increase a child's chance of being born with the disorder.CP is not hereditary.

MalaCards based summary : Cerebral Palsy, also known as infantile cerebral palsy, is related to spastic cerebral palsy and spastic paraplegia 52, autosomal recessive, and has symptoms including seizures, tremor and back pain. An important gene associated with Cerebral Palsy is ADD3 (Adducin 3), and among its related pathways/superpathways are Allograft rejection and Measles. The drugs Levodopa and Heparin have been mentioned in the context of this disorder. Affiliated tissues include Umbilical Cord and Blood, and related phenotypes are homeostasis/metabolism and nervous system

Disease Ontology : 12 A brain disease that is caused by damage to the motor control centers of the developing brain during pregnancy, during childbirth or after birth, which affects muscle movement and balance.

NIH Rare Diseases : 52 Cerebral palsy refers to a group of neurological disorders that can affect the brain and/or spinal cord. Signs and symptoms generally appear during infancy or early childhood and vary based on the type of cerebral palsy (spastic cerebral palsy, dyskinetic cerebral palsy, ataxic cerebral palsy, and mixed cerebral palsy), the severity of the condition and which area(s) of the brain are affected. Common features include a lack of muscle coordination when performing voluntary movements (ataxia ); stiff or tight muscles and exaggerated reflexes (spasticity ); walking with one foot or leg dragging; walking on the toes, a crouched gait, or a "scissored" gait; and muscle tone that is either too stiff or too floppy. Cerebral palsy is caused by abnormal brain development or damage to the developing brain. Most of these problems occur as the baby grows in the womb; however, they can happen at any time during the first 2 years of life. There is no cure for cerebral palsy, but treatment is available to alleviate some symptoms. This may include physical, occupational, and speech therapy; certain medications; surgery; and/or devices (i.e. braces, wheelchairs) to aid in mobility.

MedlinePlus : 42 Cerebral palsy is a group of disorders that affect a person's ability to move and to maintain balance and posture. The disorders appear in the first few years of life. Usually they do not get worse over time. People with cerebral palsy may have difficulty walking. They may also have trouble with tasks such as writing or using scissors. Some have other medical conditions, including seizure disorders or mental impairment. Cerebral palsy happens when the areas of the brain that control movement and posture do not develop correctly or get damaged. Early signs of cerebral palsy usually appear before 3 years of age. Babies with cerebral palsy are often slow to roll over, sit, crawl, smile, or walk. Some babies are born with cerebral palsy; others get it after they are born. There is no cure for cerebral palsy, but treatment can improve the lives of those who have it. Treatment includes medicines, braces, and physical, occupational and speech therapy. NIH: National Institute of Neurological Disorders and Stroke

CDC : 3 Cerebral palsy (CP) is a group of disorders that affect a person's ability to move and maintain balance and posture. CP is the most common motor disability in childhood. CDC estimates that an average of 1 in 323 children in the U.S. have CP.

Wikipedia : 74 Cerebral palsy (CP) is a group of permanent movement disorders that appear in early childhood. Signs and... more...

Related Diseases for Cerebral Palsy

Diseases related to Cerebral Palsy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1062)
# Related Disease Score Top Affiliating Genes
1 spastic cerebral palsy 35.4 PLP1 KANK1 GAD1 AP4B1
2 spastic paraplegia 52, autosomal recessive 34.1 AP4S1 AP4M1 AP4E1 AP4B1
3 spastic paraplegia 47, autosomal recessive 34.1 AP4S1 AP4M1 AP4E1 AP4B1
4 inherited congenital spastic tetraplegia 34.0 KANK1 GAD1 ADD3
5 spastic paraplegia 51, autosomal recessive 34.0 AP4S1 AP4M1 AP4E1 AP4B1
6 spastic paraplegia 50, autosomal recessive 34.0 AP4S1 AP4M1 AP4E1 AP4B1
7 hereditary spastic paraplegia 33.7 TUBB4A PLP1 GAD1 AP4S1 AP4M1 AP4E1
8 hypertonia 33.6 AP4S1 AP4M1 AP4B1
9 neonatal jaundice 33.4 TNF IL6 IL1B
10 quadriplegia 33.2 PLP1 KANK1 AP4S1 AP4M1 AP4E1 AP4B1
11 hereditary spastic paraplegia 51 33.1 AP4S1 AP4M1 AP4E1 AP4B1
12 paraplegia 32.6 PLP1 AP4S1 AP4M1 AP4E1 AP4B1
13 brain injury 31.9 IL6 BDNF APOE
14 gastroesophageal reflux 31.8 TNF IL6 IL1B CXCL8
15 chorioamnionitis 31.7 TNF TLR4 MMP8 IL6 IL1B CXCL8
16 pre-eclampsia 31.7 TNF TLR4 NOS3 IL6 IL1B CXCL8
17 traumatic brain injury 31.6 IL6 BDNF APOE
18 spinal cord injury 31.6 TNF IL6 CXCL8 BDNF
19 sleep disorder 31.6 TNF IL6 IL1B BDNF APOE
20 eclampsia 31.6 TNF NOS3 IL6
21 acute cystitis 31.5 TNF TLR4 IL6 IL1B CXCL8
22 encephalomalacia 31.5 TNF IL6 IL1B BDNF
23 rubella 31.4 TNF TLR4 IL6 IL1B
24 disease of mental health 31.3 TNF IL6 IL1B GAD1 BDNF APOE
25 gingivitis 31.3 TNF MMP8 IL6 IL1B CXCL8
26 speech and communication disorders 31.3 TNF IL6 BDNF APOE
27 osteoporosis 31.3 TNF TLR4 NOS3 MMP8 IL6 IL1B
28 lung disease 31.2 TNF TLR4 MMP8 IL6 IL1B CXCL8
29 sleep apnea 31.2 TNF NOS3 IL6 IL1B CXCL8 BDNF
30 respiratory failure 31.2 TNF TLR4 MMP8 IL6 IL1B CXCL8
31 funisitis 31.2 TNF MMP8 IL6 IL1B CXCL8
32 focal epilepsy 31.2 IL6 IL1B GAD1 BDNF
33 osteoarthritis 31.1 TNF IL6 IL1B CXCL8
34 toxoplasmosis 31.1 TNF TLR4 IL6 IL1B
35 inherited metabolic disorder 31.1 TNF TLR4 IL6 IL1B APOE
36 preterm premature rupture of the membranes 31.1 TNF TLR4 MMP8 IL6 IL1B CXCL8
37 cytomegalovirus infection 31.1 TNF IL6 IL1B CXCL8
38 anxiety 31.1 TNF IL6 IL1B GAD1 BDNF APOE
39 cerebrovascular disease 31.1 TNF TLR4 IL6 APOE
40 nervous system disease 31.1 TNF IL6 IL1B BDNF APOE
41 esophagitis 31.0 TNF IL6 IL1B CXCL8
42 bone resorption disease 31.0 TNF IL6 IL1B
43 placenta disease 31.0 TNF TLR4 IL6 IL1B CXCL8
44 stroke, ischemic 31.0 TNF TLR4 NOS3 IL6 IL1B BDNF
45 overnutrition 31.0 TNF TLR4 IL6 IL1B
46 periodontitis 31.0 TNF TLR4 MMP8 IL6 IL1B CXCL8
47 exanthem 31.0 TNF IL6 IL1B CXCL8
48 congenital cytomegalovirus 31.0 TNF IL1B
49 body mass index quantitative trait locus 11 31.0 TNF TLR4 NOS3 IL6 IL1B CXCL8
50 ap-4-associated hereditary spastic paraplegia 31.0 AP4S1 AP4M1 AP4E1 AP4B1

Comorbidity relations with Cerebral Palsy via Phenotypic Disease Network (PDN):

Acute Cystitis

Graphical network of the top 20 diseases related to Cerebral Palsy:

Diseases related to Cerebral Palsy

Symptoms & Phenotypes for Cerebral Palsy

UMLS symptoms related to Cerebral Palsy:

seizures, tremor, back pain, abnormality of extrapyramidal motor function, involuntary movements, dystonia, headache, torticollis, syncope, athetosis, pain, myokymia, muscle fibrillation, chronic pain, sciatica, asterixis, vertigo/dizziness, sleeplessness, muscle rigidity

MGI Mouse Phenotypes related to Cerebral Palsy:

# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.18 AP4E1 AP4M1 APOE BDNF GAD1 IL1B
2 nervous system MP:0003631 10.03 AP4B1 AP4E1 APOE BDNF GAD1 IL1B
3 adipose tissue MP:0005375 9.95 AP4E1 AP4M1 APOE IL6 NOS3 TLR4
4 muscle MP:0005369 9.92 AP4E1 APOE IL6 NOS3 PLP1 PMM2
5 respiratory system MP:0005388 9.81 AP4E1 APOE BDNF GAD1 IL6 NOS3
6 skeleton MP:0005390 9.65 AP4E1 APOE GAD1 IL1B IL6 NOS3
7 vision/eye MP:0005391 9.28 AP4E1 APOE BDNF IL6 NOS3 PLP1

Drugs & Therapeutics for Cerebral Palsy

Drugs for Cerebral Palsy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 272)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Levodopa Approved Phase 4 59-92-7 6047
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
Sodium citrate Approved, Investigational Phase 4 68-04-2
Caffeine Approved Phase 4 58-08-2 2519
Amantadine Approved Phase 4 768-94-5 2130
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
Oxytocin Approved, Vet_approved Phase 4 50-56-6 53477758 439302
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
Inulin Approved, Investigational, Nutraceutical Phase 4 9005-80-5 24763
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
15 Carbidopa, levodopa drug combination Phase 4
16 Dihydroxyphenylalanine Phase 4
17 calcium heparin Phase 4
18 incobotulinumtoxinA Phase 4
19 Acidophilus Phase 4
20 Sunflower Phase 4
21 Citrate Phase 4
22 Phosphodiesterase Inhibitors Phase 4
23 Central Nervous System Stimulants Phase 4
24 Caffeine citrate Phase 4
25 Antiviral Agents Phase 4
26 Antiparkinson Agents Phase 4
27 Dopamine Agents Phase 4
28 Hormones Phase 4
29 Respiratory System Agents Phase 4
30 Anti-Inflammatory Agents Phase 4
31 Hormone Antagonists Phase 4
32 glucocorticoids Phase 4
33 Anti-Asthmatic Agents Phase 4
Chloral hydrate Approved, Illicit, Investigational, Vet_approved Phase 3 302-17-0 2707
Peppermint oil Approved, Investigational Phase 3 8006-90-4
Peppermint Approved Phase 3
Dronabinol Approved, Illicit Phase 3 1972-08-3 16078
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
Metoclopramide Approved, Investigational Phase 3 364-62-5 4168
Clozapine Approved Phase 3 5786-21-0 2818
Bisacodyl Approved Phase 3 603-50-9
Nifedipine Approved Phase 3 21829-25-4 4485
Progesterone Approved, Vet_approved Phase 2, Phase 3 57-83-0 5994
Nitric Oxide Approved Phase 2, Phase 3 10102-43-9 145068
Scopolamine Approved, Investigational Phase 3 6533-68-2, 51-34-3 5184
Ibuprofen Approved Phase 3 15687-27-1 3672
Alendronate Approved Phase 3 66376-36-1, 121268-17-5 2088
48 Nabiximols Investigational Phase 3 56575-23-6
49 Anti-Arrhythmia Agents Phase 3
50 Neuroprotective Agents Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 1058)
# Name Status NCT ID Phase Drugs
1 Consequence of Dexmedetomidine on Emergence Deliruim After Sevoflurane Anesthesia in Children With Cerebral Palsy Unknown status NCT02244515 Phase 4 dexmedetomidine
2 Effects of Functional Electrical Stimulation on Gait in Children With Hemiplegic and Diplegic Cerebral Palsy Unknown status NCT02462018 Phase 4
3 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
4 Changes of Gas Values in Cord Blood Versus Time and Temperature Unknown status NCT02785367 Phase 4
5 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
6 A Placebo Controlled, Cross-over, Double Blind, Randomized, Clinical Trial to Compare the Efficacy and Safety of Meditoxin® Injection for Cervical Dystonia in Adults With Cerebral Palsy Completed NCT01860196 Phase 4 Meditoxin;Normal saline
7 Alterations of Functional Activities and Leg Stiffness After Hamstring Lengthening in Cerebral Palsy Children Completed NCT00154830 Phase 4
8 Recurrent Crying Spells in Cerebral Palsy With Spastic Quadriparesis - A Crossover Study Completed NCT01955655 Phase 4 Baclofen
9 Postoperative Pain in Children With Cerebral Palsy After Pelvic and Femoral Osteotomies. A Prospective, Randomized and Double-blinded Study Completed NCT00964639 Phase 4 Ropivacaine;Saline
10 Multi-center, Single Arm, Open-label, Phase IV Clinical Trial to Evaluate the Safety and Efficacy of MEDITOXIN® in Children With Cerebral Palsy Completed NCT01256021 Phase 4 Botulinum Toxin Type A
11 A Randomized Controlled Trial on Effects of Botulinum Toxin Type A in Adults With Cerebral Palsy Completed NCT00432055 Phase 4 Botulinum toxin type A (Botox);placebo (saline)
13 Effect of Erythropoietin on Preterm Brain Injury Completed NCT02036073 Phase 4 recombinant human erythropoietin
14 Efficacy of the Supplementation With a Symbiotic, a Prebiotic and a Probiotic to Produce a Beneficial Effect on the Intestinal Microbiota and on the Characteristics of Feces in Children With Cerebral Palsy (CP) and Chronic Constipation Completed NCT03117322 Phase 4
15 Effect of Magnesium Sulfate on the Incidence of Periventricular Leukomalacia in the Very Preterm Neonate Completed NCT00120588 Phase 4 magnesium
16 Magnetic Resonance Imaging and Neurodevelopmental Outcomes in Preterm Infants Following Administration of High-Dose Caffeine - A Pilot Study Completed NCT00809055 Phase 4 Caffeine citrate
17 Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity Completed NCT00178646 Phase 4 Botox
18 Use of Amantadine in Treating Cognitive and Motor Impairments in Adolescents and Adults With Cerebral Palsy Recruiting NCT04273737 Phase 4 Amantadine Hydrochloride
19 Pharmacokinetics and Safety of Treatment With Paracetamol in Children and Adults With Spinal Muscular Atrophy and Cerebral Palsy Recruiting NCT03648658 Phase 4 Paracetamol 120Mg/5mL Oral Suspension
20 Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy? Recruiting NCT02546999 Phase 4 botox;placebo
21 Efficacy of a Peri-Operative Surgical-Site, Multimodal Drug Injection in Pediatric Patients With Cerebral Palsy Undergoing Hip Surgery: A Randomized Controlled Trial Recruiting NCT04074265 Phase 4 Ropivacaine injection;normal saline
22 Reducing Neonatal Morbidity by Discontinuing Oxytocin During the Active Phase of 1st Stage of Labor: a Multicenter Randomized Controlled Trial Recruiting NCT03991091 Phase 4 discontinuation of oxytocin administration;continuation of oxytocin administration
23 A Pilot Study of Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging Active, not recruiting NCT02633241 Phase 4 Dexmedetomidine-Propofol
24 Intrathecal (IT) Baclofen Drug Distribution Pilot Study Active, not recruiting NCT02903823 Phase 4 Baclofen bolus injection
25 Improvement After Botulinum Toxin A Injections to the Upper Extremities in Children With Cerebral Palsy Terminated NCT00549471 Phase 4
26 Does Oral Baclofen Improve Care and Comfort in Spastic Children in Nursing Homes? Terminated NCT00752934 Phase 4 oral baclofen + placebo;placebo + oral baclofen
27 Randomized Trial on Efficacy and Safety of the Antenatal Rescue Course of Glucocorticoids in Threatened Premature Birth (ACG Trial) Terminated NCT00295464 Phase 4 Betamethasone sodium phos (drug)
28 Placebo Controlled Study of Baclofen for GERD in Children With Cerebral Palsy Withdrawn NCT01386255 Phase 4 Baclofen;placebo
29 Project:Intensive Habilitation (PIH) -a New Norwegian Multidisciplinary Program for Intensive Training for Children With Disabilities Unknown status NCT00202761 Phase 2, Phase 3
30 Safety and Efficacy of Bone Marrow MNC for the Treatment of Cerebral Palsy in Subjects Below Years. It is Self Funded (Patients' Own Funding) Clinical Trial Unknown status NCT01832454 Phase 2, Phase 3
31 Phase 2/3 Application of Botulinum Neurotoxin Type A in Salivary Glands as a Treatment of Chronic Drooling in Patients With Cerebral Palsy: A Controlled Clinical Trial. Unknown status NCT01489904 Phase 2, Phase 3
32 Targeted Hip Progressive Resistance Training to Improve Single Leg Balance and Walking in Children With Cerebral Palsy Unknown status NCT01633736 Phase 3
33 Magnesium Prevention of Brain Injury in Preterm Infants Unknown status NCT00065949 Phase 3 magnesium sulfate
34 Modulation of Brain Plasticity After Perinatal Stroke: The PLASTIC CHAMPS Trial Unknown status NCT01189058 Phase 2, Phase 3
35 Effect of Early Application of Recombinant Human Erythropoietin in Premature Infants on White Matter Lesions and Neurodevelopmental Outcome Unknown status NCT03110341 Phase 3 Erythropoietin;Normal saline
36 A CLINICAL STUDY TO EVALUATE THE EFFICACY OF CAUSTICUM 200C IN THE TREATMENT OF PRIMARY ENURESIS Unknown status NCT02154152 Phase 3 Homoeopathic Medicine causticum 200c
37 Effectiveness of Vojta Therapy in Motor Development of Preterm Children Unknown status NCT01838278 Phase 3
38 Double-blinded, Randomized, Active Control Comparative, Multicenter-designed, Phase III Clinical Trial to Evaluate the Safety and Efficacy of "Botulax®" Versus "Botox®" in Children With Cerebral Palsy Completed NCT01787344 Phase 3 Botulinum Toxin Type A(Botox®);Botulinum toxin type A(Botulax®)
39 Botulinum Toxin Efficiency on Spasticity of Rectus Femoris and Semitendinosus Muscles as Functional Agonist and Antagonist Muscles. Assessment of Efficiency of Botulinum Toxin on Spasticity in Agonist and Antagonist Muscles Using Clinical Assessment and Gait Analysis in Cerebral Palsy Children: Rectus Femoris and Semitendinosus Completed NCT00133861 Phase 2, Phase 3 Botulinum toxin
40 Intrathecal Baclofen. Evaluation of a Therapy for Refractory Spasticity in Children With Cerebral Palsy Completed NCT00367068 Phase 3 baclofen, intrathecal
41 Efficacy and Functional Outcomes of Botulinum Toxin A Injections to Hamstrings in Flexed Knee Gait in Cerebral Palsy: A Double-Blind, Randomized, Placebo-Controlled Trial Completed NCT00261131 Phase 3 Botulinum Toxin A
42 Integrated Management With Brain Stimulation and Hybrid Training Enhances Functional Gains in Children With Cerebral Palsy Treated by Botulinum Toxin A Completed NCT03302871 Phase 3 Botulinum toxin type A
43 Relationship of Orthotics to Activity and Participation in Children With Cerebral Palsy Completed NCT01527162 Phase 3
44 Effectiveness of Intermittent Serial Casting on Spastic Wrist Flexion Deformity in Children With Cerebral Palsy Treated By Botulinum Toxin A Completed NCT03306212 Phase 3 Botulinum toxin A
45 A Phase III, Prospective, Multicentre, Open Label, Extension Study Assessing the Long Term Safety and Efficacy of Repeated Treatment With DYSPORT® Used in the Treatment of Lower Limb Spasticity in Children With Dynamic Equinus Foot Deformity Due to Cerebral Palsy Completed NCT01251380 Phase 3
46 A Randomized Controlled Trial on Integrated Management of Pronation Deformity of Children With Cerebral Palsy Treated by Botulinum Toxin-A Completed NCT03472261 Phase 3 Botulinum toxin type A
47 Efficacy of Stem Cell Transplantation Compared to Rehabilitation Treatment of Children With Cerebral Paralysis Completed NCT01929434 Phase 3
48 A Phase III, Multicentre, Double Blind, Prospective, Randomised, Placebo Controlled Study Assessing the Efficacy and Safety of DYSPORT® Used in the Treatment of Lower Limb Spasticity in Children With Dynamic Equinus Foot Deformity Due to Cerebral Palsy Completed NCT01249417 Phase 3 Placebo
49 Individualized Neurodevelopmental Treatment Completed NCT00922077 Phase 3
50 Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy Completed NCT02002884 Phase 3 IncobotulinumtoxinA (8 Units per kg body weight);IncobotulinumtoxinA (6 Units per kg body weight);IncobotulinumtoxinA (2 Units per kg body weight)

Search NIH Clinical Center for Cerebral Palsy

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Dantrolene Sodium

Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Cerebral Palsy cell therapies at LifeMap Discovery.

Genetic Tests for Cerebral Palsy

Genetic tests related to Cerebral Palsy:

# Genetic test Affiliating Genes
1 Cerebral Palsy 29

Anatomical Context for Cerebral Palsy

MalaCards organs/tissues related to Cerebral Palsy:

Brain, Testes, Bone, Spinal Cord, Heart, Lung, Eye
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Cerebral Palsy:
# Tissue Anatomical CompartmentCell Relevance
1 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate
2 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Cerebral Palsy

Articles related to Cerebral Palsy:

(show top 50) (show all 21751)
# Title Authors PMID Year
Interventions Within the Scope of Occupational Therapy Practice to Improve Motor Performance for Children Ages 0-5 Years: A Systematic Review. 42 61
32204777 2020
Does well-functioning hand constraint induce stress in forced-use therapy for children with unilateral cerebral palsy? 61 42
32176030 2020
Hip displacement and dislocation in a total population of children with cerebral palsy in Scotland. 42 61
32114804 2020
Identification of proteolipid protein 1 gene duplication by multiplex ligation-dependent probe amplification: first report of genetically confirmed family of Pelizaeus-Merzbacher disease in Korea. 54 61
18437021 2008
Reaching movements in childhood dystonia contain signal-dependent noise. 54 61
15996397 2005
The Xq22 inversion breakpoint interrupted a novel Ras-like GTPase gene in a patient with Duchenne muscular dystrophy and profound mental retardation. 61 54
12145744 2002
Amniotic fluid matrix metalloproteinase-8 and the development of cerebral palsy. 54 61
12235718 2002
Deleterious effects of IL-9-activated mast cells and neuroprotection by antihistamine drugs in the developing mouse brain. 54 61
11477207 2001
Walking through life with cerebral palsy: reflections on daily walking by adults with cerebral palsy. 61
32238123 2020
Cardiotocograph-based labor stage classification from uterine contraction pressure during ante-partum and intra-partum period: a fuzzy theoretic approach. 61
32257127 2020
Late diagnosis of Lesch-Nyhan disease complicated with end-stage renal disease and tophi burst: a case report. 61
31985336 2020
Clinical and functional outcomes of total hip arthroplasty in patients with cerebral palsy: A systematic review. 61
32071528 2020
Evaluation of the bilateral function in para-athletes with spastic hemiplegia: A model-based clustering approach. 61
31956044 2020
Virtual keyboard with the prediction of words for children with cerebral palsy. 61
32208301 2020
Cerebral palsy is a sensorimotor disorder. 61
32484581 2020
Effect of Intravenous Aminocaproid Acid on Blood Loss and Transfusion Requirements After Bilateral Varus Rotational Osteotomy: A Double-blind, Placebo-controlled Randomized Trial. 61
32501914 2020
Self-perceived gait quality in young adults with cerebral palsy. 61
32162342 2020
Electroclinical spectrum of childhood epilepsy secondary to neonatal hypoglycemic brain injury in a low resource setting: A 10-year experience. 61
32446209 2020
Standardized Infant NeuroDevelopmental Assessment developmental and socio-emotional scales: reliability and predictive value in an at-risk population. 61
31837010 2020
Unplanned Readmissions of Children With Epilepsy in the United States. 61
32299746 2020
Improved Clinical and Functional Outcomes in Crouch Gait Following Minimally Invasive Hamstring Lengthening and Serial Casting in Children With Cerebral Palsy. 61
32501924 2020
Health-related quality of life and upper-limb impairment in children with cerebral palsy: developing a mapping algorithm. 61
32064606 2020
Evaluation of Risk Factors for Cerebrospinal Leakage in Pediatric Patients With Cerebral Palsy Treated With Intrathecal Baclofen. 61
32501926 2020
Longitudinal Development of Receptive Vocabulary in Children with Cerebral Palsy and Anarthria: Use of the MacArthur-Bates CDI. 61
31352864 2020
High levels of vitamin B12 are fairly common in children with cerebral palsy. 61
32056285 2020
Quality of Life and Health Services Utilization for Spanish Children With Cerebral Palsy. 61
32201113 2020
Understanding the impact of bilateral brain injury in children with unilateral cerebral palsy. 61
32134174 2020
Diagnosis of rhomboencephalosynapsis by MRI in a 5-year-old child. 61
32382369 2020
Effects of an intensive voice treatment on articulatory function and speech intelligibility in children with motor speech disorders: A phase one study. 61
32505858 2020
Awakening cortisol indicators, advanced glycation end products, stress perception, depression and anxiety in parents of children with chronic conditions. 61
32450487 2020
Neurodevelopmental impairment in necrotising enterocolitis survivors: systematic review and meta-analysis. 61
31801792 2020
Infantile scurvy: Still a relevant differential diagnosis in Western medicine. 61
32247222 2020
Clinical features and aetiology of cerebral palsy in children from Cross River State, Nigeria. 61
31959596 2020
Executive functions and drawing in young children with cerebral palsy: Comparisons with typical development. 61
31752569 2020
Submandibular duct ligation after botulinum neurotoxin A treatment of drooling in children with cerebral palsy. 61
32149393 2020
What's New in the Orthopaedic Treatment of Ambulatory Children With Cerebral Palsy Using Gait Analysis. 61
32501922 2020
Association of Knee Pain and Crouch Gait in Individuals With Cerebral Palsy. 61
32501923 2020
Development and Validation of a Mobile Application for Measuring Femoral Anteversion in Patients With Cerebral Palsy. 61
32501925 2020
The cardiovascular disease burden of non-traumatic fractures for adults with and without cerebral palsy. 61
32335375 2020
Selective dorsal rhizotomy for spasticity of genetic etiology. 61
32300873 2020
The phosphodiesterase-4 inhibitor Rolipram promotes cognitive function recovery in prenatal Escherichia coli infected offspring. 61
30373424 2020
Submuscular Placement of Baclofen Infusion Pumps: Case Series and Technique. 61
32149846 2020
Methodological Considerations to Investigate Dosage Parameters of Intensive Upper Limb Rehabilitation in Children with Unilateral Spastic Cerebral Palsy: A Scoping Review of RCTs. 61
31710245 2020
Congenital Malformations in Children With Cerebral Palsy: Is Prematurity Protective? 61
32386793 2020
Knee pain in children with cerebral palsy. 61
32115684 2020
Factors associated with quality of life among mothers of children with cerebral palsy. 61
31981299 2020
Antenatal corticosteroids and preterm offspring outcomes in hypertensive disorders of pregnancy: A Japanese cohort study. 61
32518309 2020
Progression of motor disability in cerebral palsy: The role of concomitant epilepsy. 61
32544658 2020
Movement Analysis in Orthopedics and Trauma Surgery - Measurement Systems and Clinical Applications. 61
31291674 2020
The importance of communication classifications in cerebral palsy registers. 61
32484918 2020

Variations for Cerebral Palsy

ClinVar genetic disease variations for Cerebral Palsy:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PMM2 NM_000303.3(PMM2):c.422G>A (p.Arg141His)SNV Pathogenic 7706 rs28936415 16:8905010-8905010 16:8811153-8811153
2 PMM2 NM_000303.3(PMM2):c.338C>T (p.Pro113Leu)SNV Pathogenic 7723 rs80338700 16:8900255-8900255 16:8806398-8806398
3 ADD3 NM_016824.5(ADD3):c.1100G>A (p.Gly367Asp)SNV Pathogenic 242273 rs564185858 10:111882007-111882007 10:110122249-110122249
4 TUBB4A NM_006087.4(TUBB4A):c.763G>A (p.Val255Ile)SNV Pathogenic/Likely pathogenic 217025 rs767399782 19:6495747-6495747 19:6495736-6495736
5 CC2D1A NC_000019.10:g.13912730_13922079deldeletion Likely pathogenic 812928 19:14023543-14032892
6 BRCA2 NM_000059.3(BRCA2):c.8487+3A>GSNV Likely pathogenic 52603 rs81002806 13:32944697-32944697 13:32370560-32370560
7 46;XX;t(1;5)(p31;q33)dnTranslocation Likely pathogenic 267832
8 46;XY;t(6;16)(p21.1;q21)dnTranslocation Uncertain significance 268038

Expression for Cerebral Palsy

Search GEO for disease gene expression data for Cerebral Palsy.

Pathways for Cerebral Palsy

Pathways related to Cerebral Palsy according to GeneCards Suite gene sharing:

(show all 43)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
5 12.37 TNF TLR4 IL1B CXCL8
Show member pathways
12.36 AP4S1 AP4M1 AP4E1 AP4B1
Show member pathways
12.31 TNF IL6 IL1B CXCL8
Show member pathways
Show member pathways
10 12.29 TNF TLR4 IL6 IL1B CXCL8
Show member pathways
Show member pathways
12.24 TNF TLR4 IL6 CXCL8
13 12.22 TNF TLR4 IL6 IL1B CXCL8
14 12.21 TNF TLR4 IL6 IL1B
Show member pathways
17 12.05 AP4S1 AP4M1 AP4E1 AP4B1
18 11.98 TNF IL6 IL1B CXCL8
19 11.97 TNF TLR4 IL6 IL1B CXCL8
Show member pathways
11.92 TNF TLR4 IL6 IL1B
22 11.91 TNF TLR4 IL1B CXCL8
23 11.86 TNF TLR4 IL6 IL1B CXCL8
24 11.83 TNF NOS3 IL6 IL1B CXCL8
25 11.77 TNF TLR4 IL6 IL1B CXCL8
26 11.72 TNF IL6 IL1B
Show member pathways
11.66 TNF IL6 IL1B CXCL8
28 11.65 TNF IL6 IL1B CXCL8
29 11.6 TNF TLR4 IL6 IL1B CXCL8
30 11.52 TNF IL6 IL1B CXCL8
31 11.51 TNF TLR4 IL1B
32 11.46 TNF IL6 IL1B APOE
33 11.39 TNF IL6 IL1B
34 11.34 NOS3 IL6 CXCL8
35 11.32 TNF TLR4 IL6 IL1B
36 11.31 TNF IL6 IL1B
37 11.31 TNF TLR4 IL6 IL1B CXCL8
38 11.29 TNF IL6 IL1B
39 11.25 TNF IL6 IL1B
41 11.05 TNF TLR4 IL6 IL1B CXCL8
42 11.04 TNF IL6 CXCL8
43 10.77 IL6 IL1B

GO Terms for Cerebral Palsy

Cellular components related to Cerebral Palsy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 trans-Golgi network membrane GO:0032588 9.46 AP4S1 AP4M1 AP4E1 AP4B1
2 clathrin adaptor complex GO:0030131 9.26 AP4M1 AP4B1
3 endosome lumen GO:0031904 9.26 AP4S1 AP4M1 AP4E1 AP4B1
4 AP-4 adaptor complex GO:0030124 8.92 AP4S1 AP4M1 AP4E1 AP4B1

Biological processes related to Cerebral Palsy according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 10.04 TNF TLR4 IL6 IL1B CXCL8
2 inflammatory response GO:0006954 9.95 TNF TLR4 PLP1 IL6 IL1B CXCL8
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.91 TNF TLR4 IL6 IL1B
4 positive regulation of gene expression GO:0010628 9.91 TNF TLR4 PLP1 NOS3 MMP8 IL6
5 protein localization GO:0008104 9.84 AP4S1 AP4M1 AP4E1 AP4B1
6 positive regulation of JNK cascade GO:0046330 9.83 TNF TLR4 MMP8 IL1B
7 cellular response to lipopolysaccharide GO:0071222 9.83 TNF TLR4 IL6 IL1B CXCL8
8 positive regulation of interferon-gamma production GO:0032729 9.78 TNF TLR4 IL1B
9 positive regulation of interleukin-6 secretion GO:2000778 9.77 TNF TLR4 IL1B
10 positive regulation of interleukin-8 production GO:0032757 9.74 TNF TLR4 IL1B
11 negative regulation of neurogenesis GO:0050768 9.73 TNF IL6 IL1B
12 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.72 TNF TLR4 IL6
13 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.71 TNF TLR4 MMP8 IL1B
14 positive regulation of chemokine production GO:0032722 9.69 TNF TLR4 IL6
15 positive regulation of glial cell proliferation GO:0060252 9.67 TNF IL6 IL1B
16 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.65 TNF TLR4
17 regulation of neuroinflammatory response GO:0150077 9.64 MMP8 IL6
18 negative regulation of lipid storage GO:0010888 9.63 TNF IL6
19 negative regulation of platelet activation GO:0010544 9.63 NOS3 APOE
20 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.63 TNF IL1B APOE
21 regulation of establishment of endothelial barrier GO:1903140 9.62 TNF IL1B
22 positive regulation of fever generation GO:0031622 9.62 TNF IL1B
23 protein targeting GO:0006605 9.62 AP4S1 AP4M1 AP4E1 AP4B1
24 regulation of microglial cell activation GO:1903978 9.59 MMP8 IL6
25 sequestering of triglyceride GO:0030730 9.58 TNF IL1B
26 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.58 TNF IL1B
27 positive regulation of nitric oxide biosynthetic process GO:0045429 9.56 TNF TLR4 MMP8 IL1B
28 lipopolysaccharide-mediated signaling pathway GO:0031663 9.46 TNF TLR4 NOS3 IL1B
29 positive regulation of interleukin-6 production GO:0032755 9.35 TNF TLR4 MMP8 IL6 IL1B
30 positive regulation of neuroinflammatory response GO:0150078 8.92 TNF MMP8 IL6 IL1B

Molecular functions related to Cerebral Palsy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 TNF IL6 IL1B CXCL8

Sources for Cerebral Palsy

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....